Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07407647 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

StatusRecruiting
PhasePhase 2
Started2026-03-12
View on ClinicalTrials.gov ↗

Amendment history

2026-04-16
minor
Study Status v1
Start dateestimated 2026-03-01→confirmed 2026-03-12
2026-02-10
minor
Original filing
This phase II trial tests the feasibility and side effects of vaginal DHEA to improve vaginal health after radiation for women with gynecologic, anal or rectal cancer. Treatment of cancers with radiation to the abdomen can influence the vaginal microbiome (any bacteria, virus, or other organisms found in the vagina). Both menopause and radiation cause a decrease in lubrication and elasticity of the vagina and symptoms including vaginal dryness, vaginal burning and itching, vaginal bleeding, pain or burning during urination, and pain during sexual intercourse. DHEA is a type of hormone replacement therapy. It is use to improve symptoms in women during menopause and may be effective in treating these symptoms for women who have received radiation.
Trial Details
NCT Number NCT07407647
Lead Sponsor Ohio State University Comprehensive Cancer Center
Conditions Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Enrollment 25 participants
Start Date 2026-03-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21